BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, February 18, 2026
Home » Newsletters » BioWorld

BioWorld

April 24, 2020

View Archived Issues
respiratory-lung-COVID-19-coronavirus.png

Mesoblast reports 83% survival in ventilator-dependent COVID-19 patients following stem cell therapy

PERTH, Australia – Australian stem cell company Mesoblast Ltd.’s shares were up nearly 39% on the news that its allogeneic cell therapy showed an 83% survival rate in ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) treated at New York’s Mount Sinai Hospital. Read More
coronavirus-COVID-19-globe.png

‘Speed and scale never before contemplated,’ as many world leaders back WHO on COVID-19 effort

LONDON – The World Health Organization (WHO) launched a global collaboration to accelerate development and production of COVID-19 vaccines, therapeutics and diagnostics, with leaders of countries around the world appearing live to pledge their support. Read More
HKEX

Akeso reaps $314M via largest IPO on HKEX this year, eyes PD-1-based bispecific

BEIJING – Pre-revenue Chinese biotech Akeso Inc., of Zhongshan, Guangdong province, launched a high-profile IPO on April 24 in Hong Kong to reap HK$2.4 billion (US$314 million), even though the economy is taking a hard hit from the COVID-19 pandemic. Read More

Market uncertainty doesn’t hinder Oric’s IPO launch

Oric Pharmaceuticals Inc. stepped into a tough economic climate on Friday when it priced its IPO of 7.5 million shares of common stock at $16 each and won the day as shares (NASDAQ:ORIC) closed at $25.77 each, 61.06% higher than they started. Read More
connected-digital-health.png

CMS, ONC offer enforcement discretion for EHR rules

The U.S. Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC) said that they will offer enforcement discretion for their respective final rules for electronic health records (EHRs), a nod to the COVID-19 pandemic. Read More
Islet clusters

Bench Press for April 24, 2020

BioWorld looks at translational medicine, including: Edited stem cells reverse mouse diabetes; Noncoding TET2 variants affect neurodegeneration risk; Pancreatic cancer uses autophagy to hide from immune system; Heart failure hormone has role in sepsis; NRF2 wakes sleeping tumor cells; Oral drug can wake up telomerase; Cheating cell death improves infarct outcomes; Older siblings’ example turns stem cells into heart cells; Lung changes from PD drug hopeful are reversible; Platelets play role in Tylenol toxicity. Read More

Appointments and advancements for April 24, 2020

New hires and promotions in the biopharma industry, including: Lumos, Y-mabs. Read More

Financings for April 24, 2020

Biopharmas raising money in public or private financings, including: Caladrius, Lineage Cell, Pluristem. Read More

In the clinic for April 24, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Bellicum, Boehringer, Chugai, GSK, Janssen, Kiromic, Merck, Novartis, Novocure, Noxxon, Sanofi, TC Biopharma, Tonix, UCB. Read More

Other news to note for April 24, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adaptvac, AGC, Agastiya, Axovant, Emergent, Johnson & Johnson, Epimab, Hoth, Voltron, Nexstim, Sanofi, Scancell, Sumitomo Dainippon, Takeda, Orifarm, Tracon. Read More

Regulatory actions for April 24, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Arch, Biosig, Innovent, Janssen, Lilly, Oryzon, Sanofi, Viralclear. Read More

Biopharma money raised: Jan. 1-April 23, 2020

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

Money raised by biopharma: 2020 vs. 2019

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019. Read More

Biggest gainers and losers for the week of April 20-24, 2020

The top 10 biopharma stock gainers and losers for the week. Read More
Acquisition-fish.png

Completed biopharmaceutical mergers & acquisitions: March 2020

Completed biopharma M&As, including: Asahi Kasei, Axim, Danaher, Domain, Foamix, GE Healthcare, Menlo, Neurofit, Prestwick Chemical, Psilocin, Recode, Revive, Sapphire, Transcriptx, Veloxis. Read More

Collaborations between biopharmaceutical companies and government/nonprofit entities: March 2020

Deals between biopharma companies and government or nonprofit entities, including: Acelrx, Allovir, Altimmune, Anabios, Arcturus, Astellas, Avectas, Berkeley Lights, Celldex, Cyclica, Daiichi Sankyo, Diverse, Dyadic, Grifols, Ideaya, IMV, Isoplexis, Janssen, Kuur, Lift, Lonza, Pluristem, Ridgeback, Shanghai Junshi, Sihuan, SK Chemicals, Themis, Wuxi Biologics, Zelluna, Ziphius. Read More

Biopharmaceutical collaborations: March 2020

Biopharma licensings, joint ventures and collaborations, including: Alector, Allogene, Alnylam, Amgen, Astellas, Astrazeneca, Bayer, Biocon, Biofrontera, Biogen, Biontech, Brightinsight, Bristol-Myers Squib, Canndoc, Celator, Codexis, Cytomx, Cytori, Debiopharm, Eli Lilly, Emergent Biosolutions, Epivax, Evotec, Forge, Forma, Fujifilm, Fujitsu, Generex, Hoth, Hypera, Ideaya, I-Mab, Immix, Isoprene, Jiangsu Alphamab, Lonza, Mannkind, Medigene, Medivir, Merck, Merrimack, Mochida, Neurorx, Nicox, Novartis, Novavax, Novotech, Oasmia, Ono, Peptidream, Pfizer, Regeneron, Revive, Sanofi, Sciclone, Shionogi, Simcere, Sorrento, Sutro, Takeda, Trianni, Ultragenyx, Vaxart, Vir, Xencor, Xoma, Zai Lab. Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing